Progenics Pharma (PGNX) Misses Q1 EPS by 5c

Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.27 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Towne Bank (TOWN) Reports In-Line Q1 EPS
• First Bancorp. (FBNC) Misses Q1 EPS by 2c